BI 1810361 (zongertinib), a potent covalent HER2 inhibitor, demonstrated an ORR of 46% in an ongoing phase I trial (NCT04886804) involving HER2-mutant NSCLC patients refractory to platinum-based chemotherapy [41]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.